NIH Extends Agreement with Galapagos Until End 2012
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Galapagos NV has announced that the U.S. National Institutes of Health (NIH) have extended their agreement with Galapagos' service division BioFocus for the operation of the Molecular Libraries Small Molecule Repository (MLSMR) through December 2012.
According to the terms of this agreement, Galapagos will be eligible to receive up to $8.6 million (€7.0 million) over the course of the two year extension.
BioFocus runs a compound management facility for a number of industrial and U.S. government customers out of its Compound Focus, Inc. subsidiary in South San Francisco. Home to the MLSMR since 2004, this facility acquires and stores compounds under the NIH contract and distributes these compounds for high-throughput biological screening throughout the NIH's academic network in the U.S.
"We are pleased that the NIH has exercised its option to extend its long-standing collaboration with BioFocus' compound management facility for another two years. BioFocus has proven that it consistently delivers a high-quality service across the vast NIH screening center network," said Onno van de Stolpe, CEO of Galapagos.
According to the terms of this agreement, Galapagos will be eligible to receive up to $8.6 million (€7.0 million) over the course of the two year extension.
BioFocus runs a compound management facility for a number of industrial and U.S. government customers out of its Compound Focus, Inc. subsidiary in South San Francisco. Home to the MLSMR since 2004, this facility acquires and stores compounds under the NIH contract and distributes these compounds for high-throughput biological screening throughout the NIH's academic network in the U.S.
"We are pleased that the NIH has exercised its option to extend its long-standing collaboration with BioFocus' compound management facility for another two years. BioFocus has proven that it consistently delivers a high-quality service across the vast NIH screening center network," said Onno van de Stolpe, CEO of Galapagos.
